# Sinclair Pharma plc

### Posting of 2009 Annual Report and Notice of AGM

**26 November 2009, Godalming, UK**: Sinclair Pharma plc (SPH:L), the international specialty pharma company, announces that it has today posted to shareholders its Annual Report and Accounts for the year ended 30 June 2009, together with notice of its annual general meeting, which is to be held at the offices of Simmons & Simmons, CityPoint, One Ropemaker Street, London EC2Y 9SS on 22 December 2009 at 10.00 a.m.

Copies of the Annual Report and Notice of AGM are available on the company's investor relations website: <a href="www.sinclairpharmair.com">www.sinclairpharmair.com</a>. In accordance with the company's obligations under Listing Rule 9.6.1, two copies of the Annual Report and Notice of AGM have been submitted to the UK Listing Authority and will shortly be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25, The North Colonnade, Canary Wharf, London, E14 5HS.

# For further information please contact:

Sinclair Pharma plc Tel: +44 (0) 1483 410 600

Dr Michael Flynn, CEO Jerry Randall, CFO

Singer Capital Markets Ltd Tel: +44 (0)20 3205 7500

Shaun Dobson Claes Spång

Capital MS&L Tel +44 (0)20 7307 5340

Mary Clark Anna Mitchell

#### Notes to Editors:

# About Sinclair Pharma Plc www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat dermatological, oral care and gynaecological diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is already present in France, Italy, and Spain, and a complementary marketing partner network that spans more than 90 countries.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.